Ontology highlight
ABSTRACT:
SUBMITTER: Westbrook TC
PROVIDER: S-EPMC9477876 | biostudies-literature | 2022 Sep
REPOSITORIES: biostudies-literature

Westbrook Thomas C TC Guan Xiangnan X Rodansky Eva E Flores Diana D Liu Chia Jen CJ Udager Aaron M AM Patel Radhika A RA Haffner Michael C MC Hu Ya-Mei YM Sun Duanchen D Beer Tomasz M TM Foye Adam A Aggarwal Rahul R Quigley David A DA Youngren Jack F JF Ryan Charles J CJ Gleave Martin M Wang Yuzhuo Y Huang Jiaoti J Coleman Ilsa I Morrissey Colm C Nelson Peter S PS Evans Christopher P CP Lara Primo P Reiter Robert E RE Witte Owen O Rettig Matthew M Wong Christopher K CK Weinstein Alana S AS Uzunangelov Vlado V Stuart Josh M JM Thomas George V GV Feng Felix Y FY Small Eric J EJ Yates Joel A JA Xia Zheng Z Alumkal Joshi J JJ
Nature communications 20220915 1
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent enza clinical resistance mechanisms have been described, including lineage plasticity in which the tumors manifest reduced dependency on the AR. To improve our understanding of enza resistance, herein we analyze the transcriptomes of matched biopsies from men with metastatic CRPC obtained prior to treatment and at progr ...[more]